The Korean Journal of Medicine

  • 제93권5호
  • /
  • Pages.430-438
  • /
  • 2018
  • /
  • 1738-9364(pISSN)
  • /
  • 2289-0769(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

타카야수동맥염의 최신 진료 및 치료 동향

Takayasu Arteritis: Update on Monitoring of Disease Activity and Management

  • 박은혜 (서울대학교 의과대학 내과학교실 류마티스내과) ;
  • 이은영 (서울대학교 의과대학 내과학교실 류마티스내과) ;
  • 송영욱 (서울대학교 의과대학 내과학교실 류마티스내과)
  • Park, Eun Hye (Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Lee, Eun Young (Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Song, Yeong Wook (Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine)
  • 발행 : 2018.10.01
⟨ 이전 논문 다음 논문 ⟩

초록

Takayasu arteritis (TAK) is a chronic inflammatory disease characterized by granulomatous vasculitis of the aorta and its major branches. The rarity of the disease along with its heterogeneous clinical presentation typically lead to late diagnosis and delayed treatment. Furthermore, clinical and serological indices for monitoring disease activity are suboptimal, with no definitive evidence supporting therapeutic approaches in TAK. Nevertheless, there have been recent advances in disease assessment with new scoring systems (Indian Takayasu Arteritis Score), biomarkers including pentraxin 3 and soluble human leukocyte antigen-E, and imaging modalities such as $^{18}F$-fluorodeoxyglucose-positron emission tomography. Most of the new information for management of TAK has come from increasing experience with biological agents, such as tumor necrosis factor inhibitors and tocilizumab, used in the treatment of resistant TAK. A number of potential new therapeutic targets that may be useful for the treatment of TAK have been reported, and randomized controlled trials are needed to establish optimal therapeutic approaches.

키워드

참고문헌

  1. Kerr GS, Hallahan CW, Giordano J, et al. Takayasu arteritis. Ann Intern Med 1994;120:919-929. https://doi.org/10.7326/0003-4819-120-11-199406010-00004
  2. Onen F, Akkoc N. Epidemiology of Takayasu arteritis. Presse Med 2017;46(7-8 Pt 2):e197-e203. https://doi.org/10.1016/j.lpm.2017.05.034
  3. Mwipatayi BP, Jeffery PC, Beningfield SJ, et al. Takayasu arteritis: clinical features and management: report of 272 cases. ANZ J Surg 2005;75:110-117. https://doi.org/10.1111/j.1445-2197.2005.03312.x
  4. Park MC, Lee SW, Park YB, Chung NS, Lee SK. Clinical characteristics and outcomes of Takayasu's arteritis: analysis of 108 patients using standardized criteria for diagnosis, activity assessment, and angiographic classification. Scand J Rheumatol 2005;34:284-292. https://doi.org/10.1080/03009740510026526
  5. Arend WP, Michel BA, Bloch DA, et al. The American college of rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 1990;33:1129-1134.
  6. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum 2013;65:1-11.
  7. Ishikawa K. Diagnostic approach and proposed criteria for the clinical diagnosis of Takayasu's arteriopathy. J Am Coll Cardiol 1988;12:964-972. https://doi.org/10.1016/0735-1097(88)90462-7
  8. Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Takayasu arteritis and giant cell arteritis: a spectrum within the same disease? Medicine (Baltimore) 2009;88:221-226. https://doi.org/10.1097/MD.0b013e3181af70c1
  9. Kim YJ, Park YS, Koo BS, et al. Immunoglobulin G4-related disease with lymphoplasmacytic aortitis mimicking Takayasu arteritis. J Clin Rheumatol 2011;17:451-452. https://doi.org/10.1097/RHU.0b013e31823ac028
  10. Craven A, Robson J, Ponte C, et al. ACR/EULAR-endorsed study to develop diagnostic and classification criteria for vasculitis (DCVAS). Clin Exp Nephrol 2013;17:619-621. https://doi.org/10.1007/s10157-013-0854-0
  11. Luqmani RA, Bacon PA, Moots RJ, et al. Birmingham vasculitis activity score (BVAS) in systemic necrotizing vasculitis. QJM 1994;87:671-678.
  12. Quartuccio L, Schiavon F, Zuliani F, et al. Long-term efficacy and improvement of health-related quality of life in patients with Takayasu's arteritis treated with infliximab. Clin Exp Rheumatol 2012;30:922-928.
  13. Misra R, Danda D, Rajappa SM, et al. Development and initial validation of the Indian Takayasu Clinical Activity Score (ITAS2010). Rheumatology (Oxford) 2013;52:1795-1801. https://doi.org/10.1093/rheumatology/ket128
  14. Direskeneli H, Aydin SZ, Merkel PA. Disease assessment in Takayasu's arteritis. Rheumatology (Oxford) 2013;52: 1735-1736. https://doi.org/10.1093/rheumatology/ket274
  15. Lagneau P, Michel JB, Vuong PN. Surgical treatment of Takayasu's disease. Ann Surg 1987;205:157-166. https://doi.org/10.1097/00000658-198702000-00010
  16. Dagna L, Salvo F, Tiraboschi M, et al. Pentraxin-3 as a marker of disease activity in Takayasu arteritis. Ann Intern Med 2011;155:425-433. https://doi.org/10.7326/0003-4819-155-7-201110040-00005
  17. Carosella ED, Paul P, Moreau P, Rouas-Freiss N. HLA-G and HLA-E: fundamental and Pathophysiological aspects. Immunol Today 2000;21:532-534. https://doi.org/10.1016/S0167-5699(00)01707-2
  18. Goel R, Kabeerdoss J, Mohan H, et al. Soluble-HLA-E: a follow up biomarker in Takayasu arteritis, independent of HLA-E genotype. Int J Rheum Dis 2018;21:532-540. https://doi.org/10.1111/1756-185X.13027
  19. Tamura N, Maejima Y, Tezuka D, et al. Profiles of serum cytokine levels in Takayasu arteritis patients: potential utility as biomarkers for monitoring disease activity. J Cardiol 2017;70:278-285. https://doi.org/10.1016/j.jjcc.2016.10.016
  20. Hartlage GR, Palios J, Barron BJ, et al. Multimodality imaging of aortitis. JACC Cardiovasc Imaging 2014;7:605-619. https://doi.org/10.1016/j.jcmg.2014.04.002
  21. Papa M, De Cobelli F, Baldissera E, et al. Takayasu arteritis: intravascular contrast medium for MR angiography in the evaluation of disease activity. AJR Am J Roentgenol 2012;198:W279-W284. https://doi.org/10.2214/AJR.11.7360
  22. Santhosh S, Mittal BR, Gayana S, Bhattacharya A, Sharma A, Jain S. F-18 FDG PET/CT in the evaluation of Takayasu arteritis: an experience from the tropics. J Nucl Cardiol 2014;21:993-1000. https://doi.org/10.1007/s12350-014-9910-8
  23. Lee KH, Cho A, Choi YJ, et al. The role of (18) F-fluorodeoxyglucose-positron emission tomography in the assessment of disease activity in patients with takayasu arteritis. Arthritis Rheum 2012;64:866-875. https://doi.org/10.1002/art.33413
  24. Karapolat I, Kalfa M, Keser G, et al. Comparison of F18-FDG PET/CT findings with current clinical disease status in patients with Takayasu's arteritis. Clin Exp Rheumatol 2013;31(1 Suppl 75):S15-S21.
  25. Cheng Y, Lv N, Wang Z, Chen B, Dang A. 18-FDG-PET in assessing disease activity in Takayasu arteritis: a meta-analysis. Clin Exp Rheumatol 2013;31(1 Suppl 75):S22-S27.
  26. Fuchs M, Briel M, Daikeler T, et al. The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis. Eur J Nucl Med Mol Imaging 2012;39:344-353. https://doi.org/10.1007/s00259-011-1967-x
  27. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009;68:310-317. https://doi.org/10.1136/ard.2008.088096
  28. Kotter I, Henes JC, Wagner AD, Loock J, Gross WL. Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature. Clin Exp Rheumatol 2012;30(1 Suppl 70):S114-S129.
  29. Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum 2007;56:1000-1009. https://doi.org/10.1002/art.22404
  30. Wen D, Du X, Ma CS. Takayasu arteritis: diagnosis, treatment and prognosis. Int Rev Immunol 2012;31:462-473. https://doi.org/10.3109/08830185.2012.740105
  31. Hoffman GS, Leavitt RY, Kerr GS, Rottem M, Sneller MC, Fauci AS. Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 1994;37:578-582. https://doi.org/10.1002/art.1780370420
  32. Hoffman GS, Merkel PA, Brasington RD, Lenschow DJ, Liang P. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 2004;50:2296-2304. https://doi.org/10.1002/art.20300
  33. Daina E, Schieppati A, Remuzzi G. Mycophenolate mofetil for the treatment of Takayasu arteritis: report of three cases. Ann Intern Med 1999;130:422-426. https://doi.org/10.7326/0003-4819-130-5-199903020-00013
  34. de Souza AW, da Silva MD, Machado LS, Oliveira AC, Pinheiro FA, Sato EI. Short-term effect of leflunomide in patients with Takayasu arteritis: an observational study. Scand J Rheumatol 2012;41:227-230. https://doi.org/10.3109/03009742.2011.633553
  35. de Souza AW, de Almeida Agustinelli R, de Cinque Almeida H, et al. Leflunomide in Takayasu arteritis - a long term observational study. Rev Bras Reumatol Engl Ed 2016;56:371-375. https://doi.org/10.1016/j.rbr.2015.09.007
  36. Wallis RS, Ehlers S. Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. Semin Arthritis Rheum 2005;34(5 Suppl1):34-38. https://doi.org/10.1016/j.semarthrit.2005.01.009
  37. Tripathy NK, Chauhan SK, Nityanand S. Cytokine mRNA repertoire of peripheral blood mononuclear cells in Takayasu's arteritis. Clin Exp Immunol 2004;138:369-374. https://doi.org/10.1111/j.1365-2249.2004.02613.x
  38. Tripathy NK, Gupta PC, Nityanand S. High TNF-alpha and low IL-2 producing T cells characterize active disease in Takayasu's arteritis. Clin Immunol 2006;118:154-158. https://doi.org/10.1016/j.clim.2005.09.010
  39. Molloy ES, Langford CA, Clark TM, Gota CE, Hoffman GS. Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis 2008;67:1567-1569. https://doi.org/10.1136/ard.2008.093260
  40. Schmidt J, Kermani TA, Bacani AK, Crowson CS, Matteson EL, Warrington KJ. Tumor necrosis factor inhibitors in patients with Takayasu arteritis: experience from a referral center with long-term followup. Arthritis Care Res (Hoboken) 2012;64:1079-1083.
  41. Mekinian A, Neel A, Sibilia J, et al. Efficacy and tolerance of infliximab in refractory Takayasu arteritis: French multicentre study. Rheumatology (Oxford) 2012;51:882-886. https://doi.org/10.1093/rheumatology/ker380
  42. Clifford A, Hoffman GS. Recent advances in the medical management of Takayasu arteritis: an update on use of biologic therapies. Curr Opin Rheumatol 2014;26:7-15. https://doi.org/10.1097/BOR.0000000000000004
  43. Comarmond C, Plaisier E, Dahan K, et al. Anti $TNF-{\alpha}$ in refractory Takayasu's arteritis: cases series and review of the literature. Autoimmun Rev 2012;11:678-684. https://doi.org/10.1016/j.autrev.2011.11.025
  44. Osman M, Aaron S, Noga M, Yacyshyn E. Takayasu's arteritis progression on anti-TNF biologics: a case series. Clin Rheumatol 2011;30:703-706. https://doi.org/10.1007/s10067-010-1658-1
  45. Serra R, Grande R, Buffone G, et al. Effects of glucocorticoids and tumor necrosis factor-alpha inhibitors on both clinical and molecular parameters in patients with Takayasu arteritis. J Pharmacol Pharmacother 2014;5:193-196. https://doi.org/10.4103/0976-500X.136101
  46. Kong X, Sun Y, Ma L, et al. The critical role of IL-6 in the pathogenesis of Takayasu arteritis. Clin Exp Rheumatol 2016;34(3 Suppl 97):S21-S27.
  47. Saadoun D, Garrido M, Comarmond C, et al. Th1 and Th17 cytokines drive inflammation in Takayasu arteritis. Arthritis Rheumatol 2015;67:1353-1360. https://doi.org/10.1002/art.39037
  48. Goel R, Danda D, Kumar S, Joseph G. Rapid control of disease activity by tocilizumab in 10 'difficult-to-treat' cases of Takayasu arteritis. Int J Rheum Dis 2013;16:754-761. https://doi.org/10.1111/1756-185X.12220
  49. Bredemeier M, Rocha CM, Barbosa MV, Pitrez EH. One-year clinical and radiological evolution of a patient with refractory Takayasu's arteritis under treatment with tocilizumab. Clin Exp Rheumatol 2012;30(1 Suppl 70):S98-S100.
  50. Abisror N, Mekinian A, Lavigne C, et al. Tocilizumab in refractory Takayasu arteritis: a case series and updated literature review. Autoimmun Rev 2013;12:1143-1149. https://doi.org/10.1016/j.autrev.2013.06.019
  51. Nakaoka Y, Isobe M, Takei S, et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis 2018;77:348-354. https://doi.org/10.1136/annrheumdis-2017-211878
  52. Mekinian A, Comarmond C, Resche-Rigon M, et al. Efficacy of biological-targeted treatments in Takayasu arteritis: multicenter, retrospective study of 49 patients. Circulation 2015;132:1693-1700. https://doi.org/10.1161/CIRCULATIONAHA.114.014321
  53. Pazzola G, Muratore F, Pipitone N, Salvarani C. Biotherapies in large vessel vasculitis. Rev Med Interne 2016;37:274-278. https://doi.org/10.1016/j.revmed.2015.08.012
  54. Salvarani C, Magnani L, Catanoso M, et al. Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford) 2012;51:151-156. https://doi.org/10.1093/rheumatology/ker296
  55. Koster MJ, Matteson EL, Warrington KJ. Recent advances in the clinical management of giant cell arteritis and Takayasu arteritis. Curr Opin Rheumatol 2016;28:211-217. https://doi.org/10.1097/BOR.0000000000000265
  56. Langford CA, Cuthbertson D, Ytterberg SR, et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of Takayasu arteritis. Arthritis Rheumatol 2017;69:846-853. https://doi.org/10.1002/art.40037
  57. Hoyer BF, Mumtaz IM, Loddenkemper K, et al. Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. Ann Rheum Dis 2012;71:75-79. https://doi.org/10.1136/ard.2011.153007
  58. Inder SJ, Bobryshev YV, Cherian SM, et al. Immunophenotypic analysis of the aortic wall in Takayasu's arteritis: involvement of lymphocytes, dendritic cells and granulocytes in immuno-inflammatory reactions. Cardiovasc Surg 2000;8:141-148. https://doi.org/10.1016/S0967-2109(99)00100-3
  59. Ernst D, Greer M, Stoll M, Meyer-Olson D, Schmidt RE, Witte T. Remission achieved in refractory advanced takayasu arteritis using rituximab. Case Rep Rheumatol 2012;2012:406963.
  60. Caltran E, Di Colo G, Ghigliotti G, et al. Two Takayasu arteritis patients successfully treated with rituximab. Clin Rheumatol 2014;33:1183-1184.
  61. Terao C, Yoshifuji H, Kimura A, et al. Two susceptibility loci to Takayasu arteritis reveal a synergistic role of the IL12B and HLA-B regions in a Japanese population. Am J Hum Genet 2013;93:289-297. https://doi.org/10.1016/j.ajhg.2013.05.024
  62. Terao C, Yoshifuji H, Nakajima T, Yukawa N, Matsuda F, Mimori T. Ustekinumab as a therapeutic option for Takayasu arteritis: from genetic findings to clinical application. Scand J Rheumatol 2016;45:80-82. https://doi.org/10.3109/03009742.2015.1060521
  63. Piggott K, Deng J, Warrington K, et al. Blocking the NOTCH pathway inhibits vascular inflammation in large-vessel vasculitis. Circulation 2011;123:309-318. https://doi.org/10.1161/CIRCULATIONAHA.110.936203
  64. Lally L, Pernis A, Narula N, Huang WT, Spiera R. Increased rho kinase activity in temporal artery biopsies from patients with giant cell arteritis. Rheumatology (Oxford) 2015;54:554-558. https://doi.org/10.1093/rheumatology/keu364
  65. Saadoun D, Lambert M, Mirault T, et al. Retrospective analysis of surgery versus endovascular intervention in Takayasu arteritis: a multicenter experience. Circulation 2012;125:813-819. https://doi.org/10.1161/CIRCULATIONAHA.111.058032
  66. Kim YW, Kim DI, Park YJ, et al. Surgical bypass vs endovascular treatment for patients with supra-aortic arterial occlusive disease due to Takayasu arteritis. J Vasc Surg 2012;55:693-700. https://doi.org/10.1016/j.jvs.2011.09.051
  67. de Souza AW, Machado NP, Pereira VM, et al. Antiplatelet therapy for the prevention of arterial ischemic events in takayasu arteritis. Circ J 2010;74:1236-1241. https://doi.org/10.1253/circj.CJ-09-0905
  68. Kazibudzki M, Tekieli Ł, Trystula M, Paluszek P, Moczulski Z, Pieniazek P. New endovascular techniques for treatment of life-threatening Takayasu arteritis. Postepy Kardiol Interwencyjnej 2016;12:171-174.
  69. Visona A, Tonello D, Zalunardo B, et al. Antithrombotic treatment before and after peripheral artery percutaneous angioplasty. Blood Transfus 2009;7:18-23.
  70. Park MC, Lee SW, Park YB, Lee SK, Choi D, Shim WH. Post-interventional immunosuppressive treatment and vascular restenosis in Takayasu's arteritis. Rheumatology (Oxford) 2006;45:600-605. https://doi.org/10.1093/rheumatology/kei245